Company Update (NYSE:TEVA): Teva Pharmaceutical Industries Ltd (ADR) Announces Relaunch of Generic Depo-Provera in the US

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy.

“This reintroduction brings an additional product to a market that was previously lacking in options,” said Dr. Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”

Teva has been committed to strengthening its generic injectable business globally, by making continued investment in newer, higher-value generic injectable products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the marketand holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Medroxyprogesterone acetate injectable suspension, USP 150 mg/mL had annual sales of approximately $211 million in the United States, according to IMS data as of July 2017.

Shares of Teva Pharmaceutical are currently trading at $17.10, down $0.09 or -0.49%. TEVA has a 1-year high of $51.15 and a 1-year low of $15.22. The stock’s 50-day moving average is $17.02 and its 200-day moving average is $27.86.

On the ratings front, TEVA has been the subject of a number of recent research reports. In a report issued on September 18, Cantor analyst Louise Chen assigned a Hold rating on TEVA, with a price target of $17, which represents a slight downside potential from current levels. Separately, on the same day, Maxim Group’s Gabrielle Zhou assigned a Hold rating to the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Louise Chen and Gabrielle Zhou have a yearly average loss of -9.2% and a return of 26.1% respectively. Chen has a success rate of 41% and is ranked #4536 out of 4653 analysts, while Zhou has a success rate of 59% and is ranked #275.

Overall, 3 research analysts have rated the stock with a Sell rating, 12 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $22.27 which is 29% above where the stock opened today.

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts